Pharma Journalist -

ImmunityBio, Inc. announced positive preclinical results for its human Ad5 vaccine candidate that contains both the spike (S) and nucleocapsid (N) SARS-CoV-2 proteins (hAd5 S + N) for…
Read More...

SMi Reports: new speaker session with Paul Roussel, Senior Director, Combination Products, at the Pre-filled Syringes East Coast 2020 conference I am pleased to inform you that Paul…
Read More...

Innovent Biologics, Inc. announced that the first patient has been successfully dosed in a Phase 1 clinical trial (CIBI322A101) of the potentially first-in-class recombinant…
Read More...

Roche announced that the U.S. Food and Drug Administration (FDA) approved Tecentriq (atezolizumab) plus Cotellic (cobimetinib) and Zelboraf (vemurafenib) for the treatment of BRAF V600…
Read More...

Pfizer Inc. and BioNTech SE announced an agreement with the Ministry of Health, Labour and Welfare (MHLW) in Japan to supply 120 million doses of BNT162 mRNA-based vaccine candidate…
Read More...

Sanofi and GSK are in advanced discussions, with the European Commission (EC) for the supply of up to 300 million doses of a COVID-19 vaccine. The vaccine candidate developed by Sanofi…
Read More...

Roche announced that the U.S. Food and Drug Administration (FDA) approved Tecentriq (atezolizumab) plus Cotellic (cobimetinib) and Zelboraf (vemurafenib) for the treatment of BRAF V600…
Read More...

SAB Biotherapeutics (SAB), a clinical stage biopharmaceutical company developing a novel immunotherapy platform to produce fully human polyclonal antibodies without the need for human…
Read More...

Teva Pharmaceutical Industries Ltd. who holds (through its Japanese affiliates) with Takeda a joint business venture in the Japanese market, announced a new strategy for its local…
Read More...

Takeda Pharmaceutical Company Limited announced that the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy Designation for its investigational drug pevonedistat for…
Read More...